The Manufacturers Life Insurance Company Has $72,000 Position in ChromaDex Co. (NASDAQ:CDXC)

The Manufacturers Life Insurance Company raised its stake in shares of ChromaDex Co. (NASDAQ:CDXC) by 75.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,732 shares of the company’s stock after purchasing an additional 8,485 shares during the period. The Manufacturers Life Insurance Company’s holdings in ChromaDex were worth $72,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of CDXC. BSW Wealth Partners acquired a new position in shares of ChromaDex during the third quarter worth approximately $324,000. WINTON GROUP Ltd bought a new position in ChromaDex during the second quarter worth $597,000. Marshall Wace LLP acquired a new position in ChromaDex during the 2nd quarter valued at $56,000. Renaissance Technologies LLC boosted its holdings in ChromaDex by 8.4% in the 2nd quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock valued at $1,136,000 after purchasing an additional 32,400 shares during the period. Finally, Rhumbline Advisers acquired a new stake in ChromaDex in the 2nd quarter worth $124,000. Institutional investors own 15.41% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on CDXC shares. StockNews.com lowered shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. HC Wainwright raised their price objective on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. Finally, Roth Mkm boosted their price objective on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th.

ChromaDex Stock Performance

Shares of ChromaDex stock opened at $6.00 on Wednesday. The firm has a market cap of $458.30 million, a P/E ratio of 592.00 and a beta of 2.16. The firm’s 50-day simple moving average is $5.71 and its 200-day simple moving average is $4.01. ChromaDex Co. has a twelve month low of $1.34 and a twelve month high of $7.97.

ChromaDex (NASDAQ:CDXC) last released its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. The company had revenue of $25.58 million for the quarter, compared to the consensus estimate of $23.70 million. During the same period in the previous year, the business earned ($0.01) earnings per share. On average, equities analysts forecast that ChromaDex Co. will post 0.04 earnings per share for the current fiscal year.

Insider Buying and Selling at ChromaDex

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the transaction, the director now directly owns 244,179 shares of the company’s stock, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 9.64% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.